These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21466844)

  • 21. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
    Derks M; Fowler S; Kuhlmann O
    Curr Med Res Opin; 2009 Apr; 25(4):891-902. PubMed ID: 19245299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents.
    Ramasamy S; Kiew LV; Chung LY
    Molecules; 2014 Feb; 19(2):2588-601. PubMed ID: 24566323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes.
    Laine K; Yasar U; Widén J; Tybring G
    Pharmacol Toxicol; 2003 Aug; 93(2):77-81. PubMed ID: 12899669
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of sarizotan metabolism: hepatic clearance, identification and characterization of metabolites, drug-metabolizing enzyme identification, and evaluation of cytochrome p450 inhibition.
    Gallemann D; Wimmer E; Höfer CC; Freisleben A; Fluck M; Ladstetter B; Dolgos H
    Drug Metab Dispos; 2010 Jun; 38(6):905-16. PubMed ID: 20219851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The inhibition of CYP1A2, CYP2C9, and CYP2D6 by pterostilbene in human liver microsomes.
    Albassam AA; Ahad A; Alsultan A; Yusufoglu HS; Foudah AI; Al-Jenoobi FI
    Pharmazie; 2021 Apr; 76(4):155-158. PubMed ID: 33849700
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC-MS/MS analysis.
    Yao M; Zhu M; Sinz MW; Zhang H; Humphreys WG; Rodrigues AD; Dai R
    J Pharm Biomed Anal; 2007 May; 44(1):211-23. PubMed ID: 17418993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase.
    Grimm SW; Dyroff MC
    Drug Metab Dispos; 1997 May; 25(5):598-602. PubMed ID: 9152599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib.
    Uttamsingh V; Lu C; Miwa G; Gan LS
    Drug Metab Dispos; 2005 Nov; 33(11):1723-8. PubMed ID: 16103134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
    Ueng YF; Hsieh CH; Don MJ
    Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
    Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
    J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.
    Stiborová M; Poljaková J; Martínková E; Ulrichová J; Simánek V; Dvořák Z; Frei E
    Toxicology; 2012 Dec; 302(2-3):233-41. PubMed ID: 22917556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of inhibitory effects of caffeic acid and quercetin on human liver cytochrome p450 activities.
    Rastogi H; Jana S
    Phytother Res; 2014 Dec; 28(12):1873-8. PubMed ID: 25196644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro modulatory effects on three major human cytochrome P450 enzymes by multiple active constituents and extracts of Centella asiatica.
    Pan Y; Abd-Rashid BA; Ismail Z; Ismail R; Mak JW; Pook PC; Er HM; Ong CE
    J Ethnopharmacol; 2010 Jul; 130(2):275-83. PubMed ID: 20457244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
    Eng H; Obach RS
    Drug Metab Dispos; 2016 Aug; 44(8):1217-28. PubMed ID: 27271369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibitory effects of wogonin on catalytic activity of cytochrome P450 enzyme in human liver microsomes.
    Li T; Li N; Guo Q; Ji H; Zhao D; Xie S; Li X; Qiu Z; Han D; Chen X; You Q
    Eur J Drug Metab Pharmacokinet; 2011 Dec; 36(4):249-56. PubMed ID: 21713461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts.
    Donato MT; Lahoz A; Jiménez N; Pérez G; Serralta A; Mir J; Castell JV; Gómez-Lechón MJ
    Drug Metab Dispos; 2006 Sep; 34(9):1556-62. PubMed ID: 16763015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of irsogladine on P450-isoform specific activities in human hepatic microsomes.
    Nakamura A; Tougou K; Kitazumi H; Yamada T; Honjou K; Nonaka K; Mukai H
    Arzneimittelforschung; 2006; 56(7):547-52. PubMed ID: 16927538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
    Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
    J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.
    Li Y; Zhou D; Ferguson SS; Dorff P; Simpson TR; Grimm SW
    Xenobiotica; 2010 Nov; 40(11):721-9. PubMed ID: 20937004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.